University of Minnesota Masonic Cancer Center and Medical Center
Welcome,         Profile    Billing    Logout  
 19 Trials 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wagner, John
NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Active, not recruiting
3
36
US
omidubicel, NiCord
Gamida Cell ltd
Hematological Malignancies
05/25
05/25
NCT02566304: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Active, not recruiting
2
35
US
Fludarabine, Fludarabine phosphate, Fludara, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Endoxan, Cytoxan, Neosar, Procytox, Revimmune, Cycloblastin, Cytophosphane, CP, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, FK-506, Fujimycin, Prograf, Advograf, Protopic, Mycophenolate mofetil, Mycophenolic acid, MMF, CellCept, Myfortic, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Malignant Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
02/24
02/24
NCT06219629: Parkinson's Disease Progression Study

Recruiting
N/A
70
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
08/25
09/25
NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

Recruiting
N/A
250
US
Umbilical Cord Blood (UCB)
Masonic Cancer Center, University of Minnesota
Lymphatic Diseases, Hematopoietic Malignancy
12/25
12/25
Tolar, Jakub
NCT02582775: MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Completed
2
17
US
Thymoglobulin, ATG, anti-thymocyte globulin, Cyclophosphamide, Cytoxan, Fludarabine, fludarabine phosphate, Fludara, Total Body Irradiation, TBI, Bone marrow infusion, HCT, Tacrolimus, Prograf, Mycophenolate Mofetil, MMF, Donor mesenchymal stem cell infusions, Busulfan
Masonic Cancer Center, University of Minnesota
Epidermolysis Bullosa
11/22
07/23
NCT01033552: Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Completed
1/2
32
US
Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Anti-thymocyte globulin, ATG, Myeloablative Busulfan, Mesenchymal stem cell transplantation, MSCT, Total body irradiation, Bone marrow or umbilical cord blood (UCG) stem cell transplantation, UCBSCT
Masonic Cancer Center, University of Minnesota
Epidermolysis Bullosa
08/21
08/21
NCT02162420: Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Active, not recruiting
N/A
57
US
Alemtuzumab, Fludarabine, Fludara, Cyclophosphamide, Total Body Irradiation, TBI, Stem Cell Transplant, HSCT, Anti-thymocyte globulin, Rabbit ATG
Masonic Cancer Center, University of Minnesota
Dyskeratosis Congenita, Aplastic Anemia
08/24
07/26
Ebens, Christen
NCT03367546: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Terminated
2
5
US
Blood and Marrow Transplant
Masonic Cancer Center, University of Minnesota
Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy, Inherited Metabolic Disorders
12/22
12/22
NCT06412497: MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting
2
60
US
Rituximab, Rabbit ATG, Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, TBI, Cell Infusion, Post-Transplant G-CSF, Filgrastim, Tacrolimus, Mycophenolate Mofetil, MMF
Masonic Cancer Center, University of Minnesota
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
05/35
05/36
NCT00357565: Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Active, not recruiting
2
33
US
filgrastim, G-CSF, busulfan, Busulfex, cyclosporine, CSA, fludarabine phosphate, Fludara, melphalan, Alkeran, mycophenolate mofetil, MMF, umbilical cord blood transplantation
Masonic Cancer Center, University of Minnesota
Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess Blasts, Refractory Anemia, De Novo Myelodysplastic Syndrome, Childhood Myelodysplastic Syndrome
06/24
12/25
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
64
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Michael Pulsipher, MD
SCID
08/26
08/26
NCT02963064: JSP191 Antibody Targeting Conditioning in SCID Patients

Recruiting
1/2
40
US
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Jasper Therapeutics, Inc.
SCID
06/25
06/28
NCT02670837: Study of Cellutome System for Treatment of Individual Lesions in EB Pts

Completed
N/A
34
US
Cellutome Epidermal Harvesting System
Masonic Cancer Center, University of Minnesota
Epidermolysis Bullosa
03/23
04/24
NCT01652092: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Recruiting
N/A
30
US
Alemtuzumab 0.3 mg, Campath-1H, Cyclophosphamide, Cytoxan, Busulfan, Myerlan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Fludara, Melphalan, Alkeran, Alemtuzumab 0.2 mg, Campath 1-H, Fludarabine phosphate 30 mg, MESNA, mercaptoethane sulfonate Na (Na being the symbol for sodium), Mesnex
Masonic Cancer Center, University of Minnesota
SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
12/25
12/26
Nelson, Kim
NCT05634512: Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.

Recruiting
N/A
24
US
Laronidase therapy and a stem cell transplant
Masonic Cancer Center, University of Minnesota
Hematopoietic Cell Transplantation, Mucopolysaccharidosis Type I
10/25
10/26
Burke, Lisa
NCT03367546: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Terminated
2
5
US
Blood and Marrow Transplant
Masonic Cancer Center, University of Minnesota
Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy, Inherited Metabolic Disorders
12/22
12/22
NCT02605421: Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting
2
12
US
Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin, Autologous Stem Cell Infusion, Granulocyte colony stimulating factor, G-CSF
Masonic Cancer Center, University of Minnesota
Neuroblastoma
10/25
12/25
NCT02171104: MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Recruiting
2
100
US
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)
Masonic Cancer Center, University of Minnesota
Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
07/25
07/28
NCT03579875: Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting
2
48
US
Total Body Irradiation (TBI) (Plan 1), TBI, Cyclophosphamide (CY) (Plan 1), CY, Fludarabine (FLU), FLU, Methylprednisolone (MP), MP, Donor mobilized PBSC infusion, PBSC, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, BU, Alemtuzumab, Melphalan, MEL
Masonic Cancer Center, University of Minnesota
Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita
01/26
01/29
NCT02179359: Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Recruiting
N/A
25
US
Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen
Masonic Cancer Center, University of Minnesota
Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
01/25
08/25
NCT01526603: High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Completed
N/A
13
US
Carboplatin, Paraplatin, Autologous stem cell infusion, Granulocyte colony stimulating factor, G-CSF, Radiation therapy, Isotretinoin (13-cis-retinoic acid), Accutane, Melphalan, Alkeran, Etoposide, Eposin, VP-16
Masonic Cancer Center, University of Minnesota
Neuroblastoma
05/23
05/23
NCT01505569: Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Completed
N/A
44
US
Ifosfamide, Mitoxana, Ifex, Etoposide, Eposin, Etopophos, Vepesid, VP-16, Mesna, Uromitexan, Mesnex, G-CSF, Granulocyte colony-stimulating factor, Busulfan, Busulfex, Melphalan, 50 mg/m2 IV over 30 min, Thiotepa, Thioplex, Autologous stem cell infusion, Radiation, Carboplatin, Paraplatin, Paclitaxel, Taxol, Onxal, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Masonic Cancer Center, University of Minnesota
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
02/24
02/24

Download Options